Citadel Advisors’s Windtree Therapeutics WINT Stock Holding History

Citadel Advisors’s Portfolio WINT Stock Details WINT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-12	Closed	-$3.77K	–	15533
2024 Q1	$3.77K	Sell	12 -30	-71%	-$11.5K	﹤0.01%	13870
2023 Q4	$27.4K	Buy	+42	New	+$37K	﹤0.01%	12338
2023 Q3	–	Sell	-24	Closed	-$27.3K	–	15223
2023 Q2	$27.3K	Buy	+24	New	+$48.7K	﹤0.01%	12452
2022 Q1	–	Sell	-1	Closed	-$66K	–	14694
2021 Q4	$66K	Buy	+1	New	+$80K	﹤0.01%	13084
2021 Q3	–	Hold	0	–	-$30K	–	14754
2021 Q2	–	Sell	-1	Closed	-$97.3K	–	13481
2021 Q1	$162K	Buy	+1	New	+$216K	﹤0.01%	11956

Other funds holding WINT

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citadel Advisors's WINT Position: Q2 2024 in Review

Citadel Advisors sold out of Windtree Therapeutics (WINT) in Q2 2024, closing a stake of 12 shares — an estimated $3.77K sold.

Citadel Advisors first reported a position in WINT in Q1 2021 and held it in 5 quarters. The position peaked at $162K in Q1 2021. 1 fund tracked by Wall St. Rank holds WINT as of Q2 2024.

Citadel Advisors reported no remaining Windtree Therapeutics position as of Q2 2024 after selling out during the quarter.
Citadel Advisors sold 12 Windtree Therapeutics shares in Q2 2024, an estimated $3.77K.
Citadel Advisors first reported a position in Windtree Therapeutics in Q1 2021 and held it in 5 quarters.
Citadel Advisors's Windtree Therapeutics position peaked at $162K in Q1 2021.
1 fund tracked by Wall St. Rank held Windtree Therapeutics as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.